GlassScriptPhysician profile
Roopal A Desa
NPI 1245345883
$3,044.92
in general payments reported to CMS, 2019-2025
20 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $271 · 2021: $333 · 2022: $167 · 2023: $555 · 2024: $791 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,701.42 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $350.89 | 2020-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $211.64 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $115.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.82 | 2025 | |
| Merck Sharp & Dohme LLC | $100.02 | 2019 | |
| Genentech USA, INC. | $70.67 | 2019 | |
| Pharmacosmos Therapeutics INC. | $58.49 | 2023 | Monoferric |
| Scilex Pharmaceuticals INC. | $56.72 | 2019 | |
| Kaleo, INC. | $52.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.89 | 2022-2023 | Jardiance |
| Amgen INC. | $28.31 | 2023-2024 | Otezla, Repatha |
| Horizon Therapeutics Plc | $26.15 | 2021 | |
| Abbvie INC. | $22.02 | 2022 | |
| Exact Sciences Corporation | $17.24 | 2023 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $17.12 | 2025 | |
| Amryt Pharma Holdings LTD | $15.76 | 2022 | |
| Athena Bioscience, LLC | $15.27 | 2024 | Nexiclon Xr |
| Teva Pharmaceuticals USA, INC. | $14.60 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopal Desa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.